A Phase 2/3, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study To Evaluate The Safety And Efficacy Of 2 Regimens Of Orally Administered PF-07321332/RITONAVIR In Preventing Symptomatic SARS-COV-2 Infection In Adult Household Contacts Of An Individual With Symptomatic COVID-19
Email for information
Research Start Date
Primary objective of this study is to evaluate the effectiveness using ritonavirin in preventing SARS-CoV-2 infection.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.